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Abstract
Background: Gadoxetic acid (Primovist™)-enhanced magnetic resonance imaging (P-MRI) scans have higher
accuracy and increased detection of small colorectal liver metastases (CRLM) compared to CT scans or conventional
MRI scans. But, P-MRI scans are still inconsistently acquired in the diagnostic work up of patients with CRLM. The
aim of this study was to determine the influence of P-MRI scans on treatment plan proposition and subsequently
the clinical course of the patient.
Methods: Eighty-three consecutive patients with potentially resectable CRLM based on a conventional CT scan
underwent P-MRI scanning prior to treatment. Treatment plans proposed by the multidisciplinary team were
compared before and after P-MRI scanning and related to the final treatment and diagnosis, the accuracy for the
CT scan and P-MRI scan was calculated.
Results: P-MRI scans led to a change of treatment in 15 patients (18%) and alteration of extensiveness of local
therapy in another 17 patients (20%). All changes were justified leading to an accuracy of 93% for treatment
proposition based on P-MRI scan, compared to an accuracy of 75% for the CT scan.
Conclusions: P-MRI scans provide additional information that can aid in proposing the most suitable treatment for
patients with CRLM and might prevent short-term reintervention.
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Background
Liver metastases arise in 50–65% of patients with colorec-
tal cancer [1, 2]. Long-term survival can be achieved with
surgical resection or local ablation therapy in patients with
resectable colorectal liver metastases (CRLM).
Imaging plays a principal role in staging of CRLM.
Nowadays, the most used imaging modalities are
contrast-enhanced computed tomography (CT) or
multi-detector row CT (MDCT). Both are limited in the
detection of nodal involvement and characterization of
small liver lesions compared to magnetic resonance
imaging (MRI) scans [3]. A CT scan has a sensitivity and
specificity of 68 and 94%, respectively, and a gadolinium
contrast-enhanced MRI scan of 90 and 87%, respectively
[4]. Different contrast agents can be administered for
contrast-enhanced hepatic MRI scans, like gadoxetic acid,
also called Primovist™ (P-MRI) (Bayer AG, Germany) [5,
6]. The reported sensitivity of P-MRI for the detection of
CRLM is 87–100% and the specificity is approximately
95% [7–9]. However, CT is still the most frequently used
to assess liver involvement and plan surgical resection
(Dutch Oncoline guidelines: CRC). P-MRI is not routinely
acquired prior to liver resection in most centers [8, 10]. In
addition, literature is lacking about the direct effect on
treatment strategy in a clinical setting, including local ther-
apy, systemic therapy or conservative treatment in a larger
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patient cohort. Therefore, there is still no convincing evi-
dence whether P-MRI scans should play a more prominent
role in the diagnostic process of patients with potential
treatable CRLM and should be standardly acquired. The
aim of this study was to determine the impact of P-MRI
scans on treatment plan proposition and subsequently the
clinical course of patients with potentially treatable CRLM,
based on preoperative CT scans.
Methods
The study was designed as a retrospective cohort study
in which consecutive patients were included. The study
was approved by the scientific review board of the De-
partment of Radiology of the Leiden University Medical
Center (LUMC) in 2017. Patient confidentiality was
guaranteed using anonymized data and radiologic im-
ages, and all data was entered into an encrypted and se-
cured database.
Patients
All patients with potential CRLM were discussed by a
multidisciplinary team (MDT) of hepatobiliary surgeons,
medical oncologists and (interventional) radiologists. In
Fig. 1 a flowchart is presented illustrating the standard
operation procedure concerning the loco regional treat-
ment of CRLM in the LUMC. Patients presented at the
MDT meeting between July 2014 and August 2017 with
primary resectable or primary irresectable (but poten-
tially resectable after conversion therapy) CRLM based
on the contrast enhanced (CE)-CT scan, of whom a
P-MRI was obtained, were included in this study. Pa-
tients with permanent irresectable CRLM were not in-
cluded. Patients who were previously treated for their
CRLM with local therapy or systemic chemotherapy
were also included. Patients in whom the time interval
between acquirement of the CT scan and P-MRI or
P-MRI and treatment was > 2 months were excluded.
Age, sex, localization of CRC, number of comorbidities,
previous surgery and/or systemic therapy for CRC, and
previous local therapy and/or systemic therapy for
CRLM were noted.
CT scan
All CT scans included an arterial phase scan and a portal
venous phase scan, using slices of 5 mm or less for re-
constructive images. Contrast-enhance CT scans ob-
tained in the LUMC were performed on a 16-slice spiral
CT (Aquillion-16, Toshiba, Tokyo, Japan) using the fol-
lowing scanning parameters: 16 × 1 mm scanning, 120
KV, rotation 0.5 s, contrast Ultravist 370 (dose weight
depended: for a standard patient (75 kg) 120 ml was
injected. Based on weight categories 46–60 kg, 60–80 kg,
80–100 kg, 100+ kg 20% more or less of the dose was
administered) with a delay of 75 s for portal venous
phase. Further parameters of CT scanning: the current
modulation for the tube varying is from 10 to 500 mA.
The pitch factor is 0.8125. Noise index with standard de-
viation of 10 is used. An Adaptive Iterative Dose Reduc-
tion (AIDR) 3D is used as reconstruction algorithm. The
reconstruction kernel is FC 18 (soft tissue filter). The
CT scans were scored for the presence, the number, lo-
cation and size of all liver metastases. All scans were
evaluated by one of four radiologists from the LUMC,
all with at least 5 years of experience in liver imaging.
P-MRI scan
All P-MRI scans were performed in the LUMC on a Philips
Ingenia 1.5 or 3.0 T. Gadoxetic acid was the intravenously
administered contrast medium (10ml Primovist). MRI se-
quences included transveral and coronal T2 TSE (TE 80
Fig. 1 Standard operation procedure concerning the loco regional treatment of CRLM in the Leiden University Medical Center
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and 250), transversal T1FFE mDIXON, diffusion weighted
imaging at b0–10–500–1000, dynamic multiphase
contrast-enhanced T1FFE images, including 20min
post-contrast images. See Additional file 1: Table S1 for
additional information about the used sequences. P-MRIs
were read by one of four dedicated abdominal radiologist,
each with at least x years of experience after board certifica-
tion in radiology. Readers were not blinded for clinical in-
formation or prior medical imaging.
Study design
All patients were discussed by the MDT, which is a weekly
meeting during which all patients who are potentially op-
erable are discussed. As stated before, Fig. 1 gives an over-
view of all possible treatment options in the LUMC.
During the first MDT meeting a treatment plan was pro-
posed based on the CT scan and classified as [1]: local
therapy, consisting of either resection, percutaneous abla-
tion or resection + ablation by radiofrequency ablation or
microwave ablation [2], conversion therapy with intent of
local therapy or [3] follow-up in case of suspicion of be-
nign lesion(s). Of note, patient with irresectable disease
were excluded. Subsequently, an P-MRI scan was made
and a treatment plan was proposed during the second
MDT meeting, potentially changing the previously pro-
posed treatment plan [1]: local therapy [2], adjustment of
the local therapy, in case the extensiveness of the local
therapy was altered [3], conversion therapy [4], palliation,
in case of diffuse disseminated disease resulting in less
than 20% of healthy liver parenchyma, or extrahepatic dis-
ease (EHD) or [5] follow-up.
Finally, the proposed treatment plan based on the P-MRI
scan was compared to the actual performed treatment.
For clarification, ‘conversion therapy’ is administered
with the purpose of reverting the disease from irresect-
able to resectable. Conversion therapy was mostly a
combination of capecitabine with oxaliplatin (CAPOX)
usually given in 3 week cycles with a maximum of eight
cycles total. ‘Palliation’ is applied if resection is not con-
sidered a (future) option.
In case the patients underwent surgery, the liver was
assessed with intra-operative ultrasound by a radiologist.
Additionally, in some patients near-infrared fluorescence
(NIRF) imaging, using indocyanine green, was per-
formed for the detection of occult liver metastases [11].
Follow-up
In case the liver lesions were resected, standard patho-
logical assessment of the lesions was performed. The
pathological assessment was used as reference. Follow-up
of the liver occurred every 4 months with CE-CT scan and
CEA serum level measurements. In case new intrahepatic
lesions were identified during the first follow-up visit,
these lesions were probably already present during the
procedure and were therefore missed on the P-MRI scan.
During the follow-up process of the patients whose lesions
were defined as benign, it became clear if these lesions
were indeed not CRLM. A minority of patients were re-
ferred back to the external hospital for follow-up.
Statistical analysis
Data were analyzed using a statistical software program
(SPSS, version 23.0). The change in treatment proposition
between MDT meeting 1 and 2 was evaluated using an in-
dependent samples t-test with standard error and 95%
confidence interval. Furthermore, an independent samples
t-test was performed for 1) comparison of the interval be-
tween the date of P-MRI scan and date of actual treatment
between the patients who underwent local therapy with-
out adjustment of the local therapy and with adjustment,
and 2) for the change in treatment proposition between
the group with CT-scan acquired in an external hospital
and in the LUMC. The statistical results were considered
to indicate significance if the P-value was less than 0.05.
Results
Patients
In total, 83 patients were included in the study cohort.
Patient and treatment characteristics are summed in
Table 1.
Treatment proposition
The type of treatment was changed in 15 patients (18%)
due to the P-MRI scans, all these changes were in con-
cordance with the actual treatment performed.
Table 1 Patient and treatment characteristics
N = 83
Age at time of CT scan; mean ± SD 64.8 ± 10.7
Sex, male; n (%) 56 (68)




≥ 2 19 (23)
Previous CRLM surgery, n (%) 18 (22)
CT scan made in LUMC, n (%) 32 (39)
Days between; mean ± SD
CT and P-MRI 29.0 ± 17.1
Days between P-MRI and treatment 28.0 ± 15.8
Actual treatment; n (%)
Local 50 (60)
Neo-adjuvant chemotherapy 15 (18)
Palliation 10 (12)
Follow-up 8 (10)
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The intended extensiveness of the local therapy was al-
tered in another 17 patients (20%) due to the P-MRI scan:
in 11 patients more malignant lesions were identified with
P-MRI (mean number additional lesions: 1.6 range; 1–3)
(mean size additional lesions: 6.7 mm; range 2–16mm),
the additional identified lesions were located peripheral,
superficial and central in the liver. In six patients less le-
sions were defined as malignant (mean number: 2.0 range;
1–6). These lesions were either considered as cysts (n = 3),
haemangiomas (n = 5), steatosis (n = 2) or could not be re-
trieved (n = 2) on the P-MRI scan.
Together the treatment plan proposition was altered
in 32 patients (38%; standard error of the mean: 5%; 95%
confidence interval: 28–49%). The treatment plan of the
remaining 51 patients (61%) was not altered. Table 2
gives an overview of the changes in treatment plan.
Actual treatment
In 56 patients the intended treatment based on the
P-MRI scan was local therapy and the extensiveness of
the local therapy was altered during the treatment in 10
patients, either more lesions (in six patients) or less le-
sions (in 4 four patients) were detected and resected
during surgery. For detection of lesions ultrasound and
NIRF imaging could be used. The additional lesions were
biopsied for histological confirmation. The patients with
lesions that could not be retrieved did not develop
CRLM during the follow-up period, so these lesions
were considered false-positive.
In five patients, who were deemed resectable on both
CT and MRI, no resection or ablation was performed be-
cause a too diffuse disease (n = 3) or too extensive
tumour burden (n = 2) was encountered during surgical
exploration. They were palliated instead.
In one patient the proposed treatment based on the
CT-scan and P-MRI was local therapy but eventually
this patient was not fit for surgery, therefore, he was
palliated.
The extensiveness of local therapy of the other 40 pa-
tients was not altered, they were treated within a mean
of 29.0 days (SD 12.6 days) after the P-MRI scan was ob-
tained, which was not significantly different from the 15
patients with adjusted local therapy (28.3 days (SD 20.7
days)) (P-value = 0.904).
In addition, there was no significant difference in
change of treatment plan between patients whose CT
scans were from external hospitals (31% change of treat-
ment) and patients whose CT scans were from the
LUMC (41% change of treatment) (p-value = 0.48).
An overview of the changes in treatment plan propos-
ition during MDT meeting 1 and 2, and the actual treat-
ment performed is given in Fig. 2.
Follow-up
All patients had a follow-up period of at least 3 months,
median follow-up period was 14.4 months (1.38–41.7).
Fifteen (18%) patients developed new intrahepatic
CRLM within a median time of 5.3 months (0.8–14.0)
after local treatment, in three of these patients the new
intrahepatic CRLM occurred within 4 months after local
therapy. Of the eight patients with lesions deemed be-
nign, the median follow-up period was 22.0 months
(4.1–41.2). One patient developed diffuse CRLM within
6 months. This patient presented with one lesion that
couldn’t be characterized on the CT scan and was
assessed as a hemorrhagic-cyst on the P-MRI, but even-
tually turned out to be a metastasis.
Accuracy
The treatment plan proposition based on the P-MRI was
accurate in 77 patients (93%). In five patients an too ex-
tensive disease was encountered during surgery and in
one patient a CRLM was characterized as a
hemorrhagic-cyst on the P-MRI scan. The treatment
plan proposition based on the CT scan of these six pa-
tients was the same as the P-MRI. The 15 changes of
treatment type due to P-MRI findings were all correct,
so the accuracy of the CT scan for treatment plan prop-
osition was accurate in 62 patients (75%).
Discussion
Our study focusses on the effect of the P-MRI on the
treatment plan proposition and clinical course in patient
with potential resectable CRLM based on CT scans. The
initial treatment plan proposal based on the CT scan
was changed in 38% of the patients due to the findings
on P-MRI scans. Compared to the final treatment, the
proposition based on the P-MRI scan was accurate in
Table 2 Comparison of the treatment plans proposed during MDT 1 and MDT 2
MDT 2
MDT 1 Local Local therapy adjustment Neoadjuvant Palliation Follow-up Total
Local 39 17 5 3 4 68
Neoadjuvant 0 0 9 1 1 11
Follow-up 1 0 0 0 3 4
Total 40 17 14 4 8 83
Changes in treatment plan are shown in bold. Extensiveness adjustment of local therapy in italic
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93% of the patients, compared to 75% of the proposi-
tions based on CT scans.
The diagnostic accuracy of the P-MRI scans in patients
with CRLM and also the impact on surgical strategy has
been previously described: in a study of Sofue et al., the
surgical strategy changed in 33% of the patients due to
the P-MRI [12]. The recent study of Jhaveri et al. de-
scribes changes in surgical strategy due to P-MRI scans
in 45% of the patients receiving neoadjuvant therapy
[13]. In contrast, Kang et al. also investigated the
changes in surgical strategy, but only changed the sur-
gery in 3% of the patients [14]. Only Vreugdenburg et al.
also determined the impact of P-MRI scans on patient
management, but only four of the 13 included studies
investigated patient outcome, mainly focusing on surgi-
cal strategy instead of treatment strategy [9].
Our single center study emphasizes not only the im-
pact of P-MRI scans on surgical strategy but on the en-
tire treatment plan proposition. The implementation of
obtaining a P-MRI scan in the diagnostic work-up of pa-
tients has several positive effects on the clinical course
of the patients. The most important consequence is the
prevention of unnecessary surgeries due to better differ-
entiation between malignancies and benign lesions on
P-MRI scans. A second advantage, which is also nicely
demonstrated by the study of Knowles et al. is the more
accurate staging based on P-MRI scans prior to conver-
sion chemotherapy, thereby reducing intra-hepatic re-
currence and avoid repeated hepatectomy [15]. In our
study more patients were treated with conversion ther-
apy prior to surgery due to new findings on the P-MRI
scan. Furthermore, in other patients the intended local
therapy was extended due to the additional identification
of small lesions with P-MRI, resulting in the prevention
of short-term reinterventions for new intrahepatic lesion
development after treatment. P-MRI scanning aids in
surgical planning, surgeons and/or interventional radi-
ologist are preoperatively better prepared in comparison
to CT scan alone, which might result in more curative
resections and less new intrahepatic CRLM formation
quickly after surgery. However, these lesions might be
detected during local treatment anyway with ultrasound
or other additional techniques as NIRF-guided surgery,
which has the potential to detect additional small super-
ficial lesion in approximately 15% of the patients [11,
16]. All current studies still advocate repeated therapy or
resection to treat all CRLM, including recurrent CRLM,
to improve survival rate [17, 18]. In addition, liver par-
enchyma sparing therapy improves 5-year survival rates,
because repeated therapy can be applied if desired [19].
Therefore, accurate imaging can aid in proposing the
most suitable treatment strategy, prevent reinterventions
and treat as liver parenchyma sparing as possible. In
combination with supplementary techniques, as NIRF
guided surgery and intraoperative ultrasound, not only
detection of CRLM will increase, also radical resection
rates will improve and reinterventions can be prevented,
all resulting in improved patient outcome. Therefore, fu-
ture studies should also focus on the bundling of all pre-
and intra-operative techniques.
Our study has several limitations. Due to the retro-
spective study design, decision making was retrospect-
ively collected, however, consecutive patients were
included and image and treatment plan evaluation dur-
ing the MDT meetings was performed in real time and
well-documented in the electronic patient charts. This
resulted also a non-standardized assessment of the scans
by four different radiologists. Differences between CT
and MRI scan could be explained due to the differences
between readers. Furthermore, readers were not blinded
Fig. 2 Changes in treatment plan and actual treatment in percentages
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for the CT scans during P-MRI assessment. However,
this resulted in a realistic representation of the “everyday
practice”. Additionally, the follow-up scans were CT
scans and not P-MRI scans because this is performed ac-
cording to the current national guidelines. Time-interval
between obtaining the P-MRI scan and the actual treat-
ment might be of influence. But, we found no significant
differences for both the origin of acquirement of CT
scans or for the time-interval. Sensitivity and specificity
could not be calculated based on our study results with-
out introducing bias. Moreover, sensitivity and specificity
have been examined extensively in multiple studies, and
will be of no additional value. Finally, we can interpret
our results only by looking at the patient’s clinical
course, based on which the treatment plan proposition
using P-MRI had an accuracy of 93%. However, we have
no proof that these treatment propositions were superior
to the treatment propositions based on the CT scans, es-
pecially, those in whom the patients were administered
conversion therapy instead of upfront local therapy, as
described above.
To conclude and most importantly, our study is a dis-
play of the clinical decision making in a Dutch academic
center, underlining the added value of a P-MRI scan in the
entire treatment process of CRLM, improving cancer care
and clinical outcome for these patients. In which we
showed that P-MRI scans provide additional information
that can aid in proposing the most suitable treatment and
might prevent short-term reintervention of patients with
CRLM. Incorporating an P-MRI scan in the work-up of
CRLM patients can improve treatment proposition and
clinical outcome compared to CT scanning alone.
Additional file
Additional file 1: MRI scan protocols 1.5 Tesla and 3 Tesla Ingenia. Both
scanning protocols of 1.5 T and 3 T Ingenia are displayed in a table in the
order of acquiring the sequences. (DOCX 20 kb)
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